Boston Migraine and Contraception Study

The Boston Migraine and Contraception Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01216358

Acronym

BMAC

Enrollment

171

Registered

2010-10-07

Start date

2010-10-31

Completion date

2011-12-31

Last updated

2012-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Headache

Keywords

Headache, Contraception

Brief summary

The objectives of this prospective, descriptive study are to: 1. generate estimates of the incidence, prevalence, persistence, clinical impact and attributable risk of migraine due to hormonal contraception (HC) use; and 2. identify predictive factors for clinically significant changes in headache attributable to HC use. The investigators hypothesize that: 1. Most women with pre-existing migraine will have no significant change from baseline headache frequency or clinical impact attributable to HC at 3 months following initiation; a minority will report clinically significant worsening or improvement 2. The incidence of headache and migraine in HC users will not be significantly different from their incidence in NHC users 3. There will be identifiable risk factors for development or worsening of headache/migraine in the minority of HC users where that occurs.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Proficiency in English * Medically eligible for her chosen form of contraception per standard PPLM clinic protocol * (For Study Arm A) Desire initiation of an estrogen/progesterone contraceptive method at time of clinic presentation and evaluation * (For Study Arm B) Desire initiation of a progesterone only contraceptive method at time of clinic presentation and evaluation * (For Control Arm) Initiating a non-hormonal contraceptive, or not initiating any contraceptive method * (For Control Arm) Stated intention of not initiating any hormonal contraception over the 3 month study period * Agreeing to study procedures

Exclusion criteria

* Inability to speak and read English * (For Control Arm) Use of hormonal contraceptive in the past 3 months * (For Control Arm) Been pregnant in the past 3 months * States an intention to discontinue use of their newly initiated contraceptive (or lack of contraceptive) before the end of the 3 month study period * Unwilling or unable to comply with study follow-up procedures * Inability to give informed consent * Previous participation in this study

Design outcomes

Primary

Measure	Time frame	Description
Proportion of days with headache	84 days	Our primary outcome is the change in the proportion of headache days over 84 days, adjusted for baseline headache frequency

Secondary

Measure	Time frame	Description
Averages for percentage of headache days/28 days	84 days	Our secondary outcome will compare averages for the percentage of headache days/28 days for the days 1-28, days 29-56 and days 57-84, adjusted for baseline frequency

Countries

United States

Outcome results